Evidence map›Paper›PMID 39315323›Full record

ArticleHemaSphere2024

Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS.

Paolo Mazzeo, Christina Ganster, John Wiedenhöft, Katayoon Shirneshan, Katharina Rittscher, Elzbieta B Brzuszkiewicz, Doris Steinemann, Maximilian Schieck, Catharina Müller-Thomas, Hannes Treiber and 8 more

Abstract read
In one paragraph

Article in HemaSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Paolo MazzeoDepartment of Hematology and Medical Oncology, INDIGHO laboratory University Medical Center Göttingen (UMG) Göttingen Germany.ORCID 0000-0001-6317-0216
Christina GansterDepartment of Hematology and Medical Oncology, INDIGHO laboratory University Medical Center Göttingen (UMG) Göttingen Germany.
John WiedenhöftDepartment of Human Genetics University of Leipzig Medical Center Leipzig Germany.
Katayoon ShirneshanDepartment of Hematology and Medical Oncology, INDIGHO laboratory University Medical Center Göttingen (UMG) Göttingen Germany.
Katharina RittscherDepartment of Hematology and Medical Oncology, INDIGHO laboratory University Medical Center Göttingen (UMG) Göttingen Germany.
Elzbieta B BrzuszkiewiczDepartment of Hematology and Medical Oncology, INDIGHO laboratory University Medical Center Göttingen (UMG) Göttingen Germany.
Doris SteinemannDepartment of Human Genetics Hannover Medical School Hannover Germany.
Maximilian SchieckDepartment of Human Genetics Hannover Medical School Hannover Germany.
Catharina Müller-ThomasDepartment of Medicine III Technical University of Munich School of Medicine and Health Munich Germany.
Hannes TreiberDepartment of Hematology and Medical Oncology, INDIGHO laboratory University Medical Center Göttingen (UMG) Göttingen Germany.
Friederike BraulkeDepartment of Hematology and Medical Oncology, INDIGHO laboratory University Medical Center Göttingen (UMG) Göttingen Germany.
Ulrich GermingDepartment of Hematology, Oncology and Clinical Immunology Heinrich-Heine-Universität Düsseldorf Germany.
Katja SockelMedical Clinic and Policlinic I University Hospital Carl Gustav Carus Dresden Dresden Germany.
Ekaterina BalaianMedical Clinic and Policlinic I University Hospital Carl Gustav Carus Dresden Dresden Germany.
Julie SchanzDepartment of Hematology and Medical Oncology, INDIGHO laboratory University Medical Center Göttingen (UMG) Göttingen Germany.
Uwe PlatzbeckerMedical Clinic and Policlinic 1, Hematology and Cellular Therapy Leipzig University Hospital Leipzig Germany.
Katharina S GötzeDepartment of Medicine III Technical University of Munich School of Medicine and Health Munich Germany.
Detlef HaaseDepartment of Hematology and Medical Oncology, INDIGHO laboratory University Medical Center Göttingen (UMG) Göttingen Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The acquisition of subsequent genetic lesions (clonal evolution, CE) and/or the expansion of existing clones (CEXP) contributes to clonal dynamics (CD) in myelodysplastic syndromes (MDS). Although CD plays an important role in high-risk patients in disease progression and transformation into acute myeloid leukemia (AML), knowledge about CD in lower-risk MDS (LR-MDS) patients is limited due to lack of robust longitudinal data considering the long clinically stable courses of the disease. In this retrospective analysis, we delineate the frequency and the prognostic impact of CD in an unselected real-world cohort of LR-MDS patients. We screened 68 patients with a median follow-up of 40.5 months and a median of 7.5 (range: 2-22) timepoints for CE and CEXP detected by chromosomal banding analysis, fluorescence in situ hybridization, sequencing, and molecular karyotyping. In 30/68 patients, 47 CE events and a CD rate of 1 event per 4 years were documented. Of note, patients with at least 1 CE event had an increased probability for subsequent treatment. Unexpectedly, CE did not correlate with inferior outcomes, which could be reasonably explained by CD detection triggering the subsequent start of a disease-modifying therapy.

Identifiers

PMID39315323
PMCPMC11417473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.